Results 161 to 170 of about 165,259 (299)
Sodium Channel-Mediated Ventricular Arrhythmia After Delphinium denudatum Ingestion Managed Conservatively in a Resource-Limited Setting. [PDF]
Rassani N, Grauer K.
europepmc +1 more source
Iron deficiency in heart failure: Epidemiology, diagnostic criteria and treatment modalities
ESC Heart Failure, Volume 12, Issue 2, Page 723-726, April 2025.
Stephan von Haehling
wiley +1 more source
This study analyzed 236 heart failure with preserved ejection fraction (HFpEF) pharmacological trials registered on ClinicalTrials.gov from 2003 to 2025, revealing a post‐2016 surge (76.3%), U.S. dominance (58.5%), and prominence of SGLT2 inhibitors/novel therapies (each 13.1%).
Yucheng Hou +6 more
wiley +1 more source
Ventricular Arrhythmia as a Presenting Feature in a Patient With Tubercular Myocarditis and Axillary Lymphadenopathy. [PDF]
Nissar K +3 more
europepmc +1 more source
Beyond Traditional Screening: The Future of Heart Failure Detection With Biomarkers and AI
Advancing HF Screening: Integrating Technology and Risk Factors Across Eras. This diagram provides a comprehensive review of the historical developments and projected trends of heart failure (HF) screening methodologies, with the prevalent risk factors for HF depicted at the base.
Xiaofeng Fang +9 more
wiley +1 more source
Alternative Approaches to Bilateral Stellate Ganglion Block for Treatment of Refractory Ventricular Arrhythmia. [PDF]
Skinner C +6 more
europepmc +1 more source
Magnetocardiography (MCG) enables non‐invasive mapping of cardiac magnetic fields. In this study, an MCG‐based machine learning model detects pulmonary hypertension with robust performance. Furthermore, MCG features may improve the accuracy of short‐term risk assessment.
Yuankun Qi +11 more
wiley +1 more source
Ultrasound-Guided Regional Anesthesia for Repeat Ventricular Arrhythmia Catheter Ablation: A Case Report. [PDF]
Farokhnia R +4 more
europepmc +1 more source
ABSTRACT One of the most serious complications associated with the use of the chemotherapeutic agent doxorubicin (DOX) is cardiomyopathy. Although cardioprotective drugs such as angiotensin receptor‐neprilysin inhibitors (ARNI) are used to prevent cardiomyopathy in DOX patients, no studies have reported the relationship between ARNI and endoplasmic ...
Mert Unvan +3 more
wiley +1 more source

